Why RAC ASX (Race Oncology Limited) could be a good investment?
- The company has a strong pipeline of products. RAC ASX is developing a number of potential new drugs, including Zantrene, which is in Phase 2 clinical trials for the treatment of clear cell renal cell carcinoma (ccRCC). ccRCC is a type of kidney cancer that is difficult to treat and has a high mortality rate. If Zantrene is successful, it could be a major commercial success.
- The company has a experienced management team. RAC ASX's management team has a lot of experience in the pharmaceutical industry. They have a proven track record of developing and commercializing new drugs.
- The company is well-funded. RAC ASX has a strong balance sheet and has raised enough money to fund its development programs for the next few years.
- Forums
- ASX - By Stock
- RAC - Charts & Price Action
Why RAC ASX (Race Oncology Limited) could be a good...
-
- There are more pages in this discussion • 5,809 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.84 |
Change
-0.035(1.87%) |
Mkt cap ! $308.3M |
Open | High | Low | Value | Volume |
$1.88 | $1.88 | $1.79 | $112.7K | 61.76K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2370 | $1.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.84 | 581 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2370 | 1.825 |
2 | 1815 | 1.820 |
2 | 2200 | 1.815 |
4 | 56929 | 1.810 |
2 | 2226 | 1.805 |
Price($) | Vol. | No. |
---|---|---|
1.840 | 581 | 1 |
1.850 | 287 | 1 |
1.855 | 4569 | 1 |
1.860 | 4000 | 1 |
1.875 | 198 | 1 |
Last trade - 14.06pm 18/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |